Several analysts have recently updated their ratings and price targets for The Cooper Cos. (NYSE: COO):

  • 9/11/2016 – The Cooper Cos. had its “hold” rating reaffirmed by analysts at Wells Fargo & Co..
  • 9/9/2016 – The Cooper Cos. had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $215.00 price target on the stock.
  • 9/2/2016 – The Cooper Cos. had its “in-line” rating reaffirmed by analysts at Stifel Nicolaus.
  • 9/2/2016 – The Cooper Cos. had its price target raised by analysts at BMO Capital Markets from $199.00 to $206.00. They now have an “outperform” rating on the stock.
  • 8/31/2016 – The Cooper Cos. had its price target raised by analysts at Stifel Nicolaus from $195.00 to $215.00. They now have a “buy” rating on the stock.
  • 8/24/2016 – The Cooper Cos. had its price target raised by analysts at Jefferies Group from $190.00 to $210.00. They now have a “buy” rating on the stock.
  • 8/18/2016 – The Cooper Cos. had its price target raised by analysts at Robert W. Baird from $185.00 to $196.00. They now have an “outperform” rating on the stock.
  • 8/5/2016 – The Cooper Cos. was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “The Cooper companies top-line growth in fiscal 2016 is expected to be driven by the strength at the CooperSurgical segment. The company's growing presence in the women's healthcare market through accretive acquisitions is positive in our view. Moreover, the rollout of MyDay and Clariti lenses in the domestic market will drive top-line growth. It is also expected to benefit largely from the manufacturing platform and formulation expertise of Sauflon. The benefit, translating into lower production costs, will improve profitability. Meanwhile, estimates have been stable lately ahead of the company’s third-quarter earnings release. We note that the company has positive record of earnings surprises in recent quarters. However, unfavorable foreign exchange rate, intensifying competition, volatility at distributor base and higher leverage are the primary headwinds.”
  • 7/26/2016 – The Cooper Cos. had its “overweight” rating reaffirmed by analysts at Piper Jaffray Cos.. They now have a $185.00 price target on the stock.

Shares of The Cooper Cos. (NYSE:COO) traded down 0.71% during trading on Wednesday, reaching $185.09. 602,089 shares of the company’s stock were exchanged. The Cooper Cos. has a 52 week low of $119.28 and a 52 week high of $190.99. The stock has a market capitalization of $9.02 billion, a PE ratio of 36.24 and a beta of 0.20. The company’s 50-day moving average is $184.48 and its 200 day moving average is $167.76.

The Cooper Cos. (NYSE:COO) last posted its quarterly earnings data on Thursday, September 1st. The medical device company reported $2.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.29 by $0.01. The company had revenue of $514.70 million for the quarter. The Cooper Cos. had a net margin of 13.14% and a return on equity of 14.89%. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.97 EPS. On average, analysts forecast that The Cooper Cos. will post $8.43 earnings per share for the current year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/weekly-investment-analysts-ratings-updates-for-the-cooper-cos-coo.html

In related news, Director William A. Kozy purchased 270 shares of the firm’s stock in a transaction dated Tuesday, September 6th. The stock was acquired at an average price of $186.69 per share, with a total value of $50,406.30. Following the completion of the transaction, the director now owns 770 shares of the company’s stock, valued at $143,751.30. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Robert S. Weiss sold 151,839 shares of the firm’s stock in a transaction that occurred on Monday, June 27th. The stock was sold at an average price of $163.02, for a total transaction of $24,752,793.78. Following the sale, the chief executive officer now directly owns 200,617 shares of the company’s stock, valued at approximately $32,704,583.34. The disclosure for this sale can be found here. Insiders own 2.20% of the company’s stock.

The Cooper Companies, Inc (Cooper) is a medical device company. The Company operates through two business units: CooperVision, Inc (CooperVision) and CooperSurgical, Inc (CooperSurgical). CooperVision develops, manufactures and markets a range of soft contact lenses for the vision correction market. CooperVision offers Biofinity monthly spherical, toric and multifocal lenses under the Avaira brand.

5 Day Chart for NYSE:COO

Receive News & Ratings for The Cooper Cos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Cooper Cos and related companies with MarketBeat.com's FREE daily email newsletter.